Lv41
450 积分 2021-11-08 加入
From Rarity to Reality: Osimertinib's Promising Horizon in Treating Uncommon EGFR Mutations in Non-Small Cell Lung Cancer
6小时前
待确认
Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene–Driven Non–Small Cell Lung Cancer (TURBO-NSCLC)
6小时前
已完结
Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer
2天前
已完结
Neoadjuvant immunotherapy strategies for resectable non-small cell lung cancer (NSCLC): Current evidence among special populations and future perspectives
2天前
已完结
Finding One Treatment for All Advanced EGFR-positive NSCLC—An Infinite Task
2天前
已完结
Artificial Intelligence Enhances NSCLC Care by Predicting Treatment Outcomes, Validating Neoadjuvant Therapies, and Improving Precision
2天前
已完结
Management of locally advanced non‐small cell lung cancer: state of the art and future directions
2天前
已完结
Liquid biopsy for the management of NSCLC patients under osimertinib treatment
2天前
已完结
Immunotherapy in resectable NSCLC: Answering the question or questioning the answer?
2天前
已完结
Real-World Genomic Profile of EGFR Second-Site Mutations and Other Osimertinib Resistance Mechanisms and Clinical Landscape of NSCLC Post-Osimertinib
2天前
已完结
皖公网安备34019202002308
